BioSpace News Archive

Business

Atea Pharmaceuticals Appoints Polly Murphy, D.V.M, Ph.D., to the Board of DirectorsPharmaceutical executive brings 20 years of clinical, commercial and operational leadership

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, announced the appointment of Polly Murphy, D.V.M., Ph.D., Chief Business Officer of UroGen Pharma, to its Board of Directors.

September 14, 2020
·
2 min read
Business

Vizgen Taps Akoya Biosciences Executive Terry Lo As New President and CEO

Vizgen, the company illuminating biology with the next generation of spatially resolved, single-cell genomics tools, announced the appointment of Terry Lo as President and Chief Executive Officer, effective immediately.

September 14, 2020
·
3 min read
Pharm Country

Post Acute Medical (PAM) Deploys Biodefense Indoor Protection System Shown to Kill COVID-19 Virus at Three Hospitals

Post Acute Medical, LLC announced that it has deployed Integrated Viral Protection’s indoor biodefense system at three of its specialty hospital locations in Las Vegas, Nevada, Victoria, Texas, and San Antonio, Texas as part of the company’s commitment to delivering important health services safely.

September 14, 2020
·
2 min read
Policy

Seneca Therapeutics, Inc. Receives Positive Feedback from FDA on Reactivation of the SVV-001 IND and Phase I/II Protocol

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immunotherapeutics for cancer based on Seneca Valley Virus, announced the receipt of positive guidance from the FDA on the reactivation of the SVV-001 IND and Phase I/II protocol.

September 14, 2020
·
3 min read
Pharm Country

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities

September 14, 2020
·
6 min read
BioMidwest

Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial

Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

September 14, 2020
·
15 min read
Policy

Mallinckrodt Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)

Company remains committed to working with FDA toward an approval for this important potential therapy

September 14, 2020
·
8 min read
Pharm Country

Zynerba Pharmaceuticals Provides Update on Recent Milestones

Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel™ in Children and Adolescents with Fragile X Syndrome and a Fully Methylated FMR1 Gene

September 14, 2020
·
6 min read
Business

Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine

Dynavax will provide CpG 1018 to produce up to 190 million doses over a five year period to support Valneva’s contract with the U.K. government

September 14, 2020
·
8 min read
Policy

FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Dupixent® for the treatment of patients 12 years and older with eosinophilic esophagitis.

September 14, 2020
·
19 min read